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health law conditions. METHODS: The survey was done in
Košice district, Slovak republic (free access only to OTC drugs in
pharmacies) and in Novi Sad district, Serbia (free access to most
of the drugs on market in pharmacies). A total of 500 families in
both districts with small children, only adult members and fami-
lies with old residents were included. All drugs in home cabinets
were notiﬁed as well as expiration date, way of obtaining the
medicines (freely or on prescription). Family members were inter-
wieved about the drugs. RESULTS: The most of the drugs left
from the last treatment (Slovak republic), but in many families
there were also non opened packages of the drugs (Serbia). In
Slovak republic, the most of the un-opened drugs belonged to
OTC preparations—nonsteroidal anti-inﬂammatory drugs, and
about 60% of the families were aware of the main possible side
effects. In Novi Sad district drugs belonging to all groups, includ-
ing antibacterials, were kept at homes as reserves. The numbers
of the drug packages in families in both countries was from 1 to
more than 30. In both countries there were packages with
expired date of use. Pharmacoekonomic calculations showed
that amount of the money trapped in home cabinets are substan-
tial in both countries. It ranged from few EU to 300 EU/home. In
both countries, unused drugs are at the end throwed as garbage,
without returning to pharmacy. CONCLUSION: Educational
efforts are needed to improve the attitudes of the residents in
order to decrease the amount of drug reserves. The initiative
aimed to change the amount of pills in packages is also needed.
PIH11
ROLE OF BLACK BOX WARNINGS AND FORMULARY
MANAGEMENT
Cohen JP1,Young B2
1Erasmus University, Rotterdam,The Netherlands, 2Tufts University,
Boston, MA, USA
OBJECTIVES: The Centers for Medicare and Medicaid Services
(CMS) has stipulated regulations requiring coverage of “all or
substantially all” drugs in six therapeutic categories deemed
“medically necessary:” antineoplastics, HIV/AIDS medications,
immunosuppressants, antidepressants, anticonvulsants, and
antipsychotics. CMS allows formulary managers to exclude
drugs on the basis of safety, for example, drugs with “black box”
warnings (BBWs). First, we analyzed compliance with CMS regu-
lations among 36 leading prescription drug plans (PDPs) partici-
pating in the Medicare prescription drug beneﬁt. Next, we
examined whether plans excluded from coverage or added more
formulary restrictions to drugs with black box warnings than to
drugs without. METHODS: Utilizing databases at the Tufts
Center for the Study of Drug Development, we identiﬁed 197
drugs across all six categories, approved by the Food and Drug
Administration between 1962 and 2007. Next, we analyzed 36
PDP formularies. Speciﬁcally, for all 197 drugs we gathered data
on prices, formulary (tier) placement, cost sharing, and formu-
lary restrictions. Our primary source for formulary data was the
CMS website and its “Prescription Drug Plan” ﬁnder. RESULTS:
Plans are not complying with the “all or substantially all” regu-
lations. Across all six therapeutic categories, an average of 15%
of drugs is not on plan formularies, with a higher percentage of
exclusions among antidepressants and anticonvulsants. In addi-
tion, drugs with BBWs tend to be excluded from PDP formularies
more frequently than those without BBWs, and to have more
formulary restrictions. CONCLUSION: Non-compliance with
CMS regulations suggests CMS oversight is lacking. Further,
plans appear to use BBWs justify formulary exclusions and
restrictions. Research needs to be done to determine whether on
balance such exclusions and restrictions are deleterious to ben-
eﬁciary outcomes.
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OBJECTIVES: Due to an increase in the number of cardiovas-
cular events, breast cancer, stroke and pulmonary embolism
among menopausal women who took estrogen/gestagen com-
binations, hormone therapy (HT) is criticised. International
ﬁgures suggest that the application of hormones has consider-
ably decreased since the publication of the WHI study, evidence
for Germany is yet not available. Our objective was to clarify if
and how prescription patterns have changed in Germany after
the WHI study. METHODS: In a longitudinal retrospective
cohort study using Statutory Health Insurance (SHI) claims data
of 1.5 million beneﬁciaries, the prescription patterns of hor-
mones among menopausal women were investigated. RESULTS:
A total of 134,683 women (mean age 54 years) who where
continuously enrolled from 2000 until 2005 could be identiﬁed
in the SHI data set. Of those, 38,897 (29%) received in the
observation period at least one prescription of a drug which is
approved for HT. The comparison of women who received
those prescriptions only before the publication of the WHI
study (January 2000 till July 2002) with women who received
HT after WHI (February 2003 till December 2005) shows a
decrease in the number of women treated with hormones by a
total of 18.1%. The strongest decrease can be observed in the
oral estrogen/gestagen combination drugs (10.4%) and estrogen
single-compound drugs (2.6%). Before WHI, n = 2674 women
received a prescription of ﬁxed estrogen/gestagen combinations.
The analysis of incident HT resulted in a decrease in the number
of women with prescriptions after WHI by n = 341. Related to
the study population (n = 38,897) this equals a decrease of
0.9%. CONCLUSION: Although the number of HT prescrip-
tions has decreased in the observation period, surprisingly after
the publication of the WHI study still relatively many hormone
treatments are undertaken or even commenced. How far the
decrease has dynamically changed since summer 2002 is cur-
rently under examination.
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OBJECTIVES: To create a framework to analyze the cost-
effectiveness of mammography screening designed speciﬁcally
to isolate the effect of mammography on life expectancy (LE)
with breast cancer (BC). METHODS: Interventions: Base-case:
Annual mammography from the age of 40 vs. no mammography.
Design: Lifetime horizon, societal perspective for a white female
population aged 40 and over. Age-speciﬁc discounted quality-
adjusted LE and lifetime costs were simulated by backwards
induction for each intervention, starting the analysis at age 80,
and used to calculate the incremental cost-effectiveness ratio
(ICER) at ﬁve-year intervals. Costs: Direct and indirect costs
associated with mammography, its workup and BC management.
Effectiveness: LE was estimated using the DEALE method.
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